Effectuating Process Improvement through Better Equipment Handling in Component Laboratory
electronic scale calibration values would automatically be verified each time. [4] However, sometimes when excessive stress is applied while hanging the blood bags onto the hooks of the electronic weighing scales, the linearity of scales gets disturbed. There was an error alert message "Check buffy-coat scale" that appeared on the display screen. This alteration in the linearity of the scales had incidentally collected higher dry BC and lower BC dilution volume. By reason of the said error, as a result, the platelet quality was affected. In view of the corrective action, the engineer advised us telephonically, to raise the BC set voltage to 150 mv from the altered 100 mv and recalibrate the OOT weighing scales using the standard weight of 200 g. The resident doctor further performed the quality analysis on all the BC-PC prepared from that particular instrument. All the previous, five out of specification (OOS) units (low in yield and volume) were labeled appropriately and discarded as per department protocol. On preventive mode, all the technicians were reoriented about the importance of adherence to the work instructions before using any equipment.
Sir, Adherence to current Good Manufacturing Practices ensures that each product meets the quality requirements as per the marketing authorization or product specifications. [1] According to FDA, every equipment must be standardized and maintained as prescribed in the written instructions and must perform in the manner for which it is designed so as to ensure compliance with the standards. [2] Periodic calibration to specified tolerances using approved procedures is an imperative element of any quality system. Therefore, all equipment must be evaluated with accuracy for their optimal functionality. Further national guidelines like Director General of health Services provide quality benchmarks for blood components. [3] Conformance to the quality requirements is dependent on several factors such as donor-related biological variables (platelet count and/or total mass), storage bags, type of anticoagulant used, storage temperature, preparation methodology, and equipment used in the manufacturing process. Any deviation from the protocol demands a prompt corrective and preventive action (CAPA).
One such event occurred in the month of October 2014 when five units of buffy coat reduced platelet concentrates (BC-PC) with low volume and yield were obtained at the component laboratory [ Table 1 ]. The laboratory technician informed about the same to the resident posted there. CAPA was initiated and subsequently we contacted the engineer. We noticed that the electronic weighing scales of the Terumo Automated Component Extractor II+ (Terumo Penpol Pvt. Ltd.) were lying out-of-tolerance (OOT) and needed an immediate corrective action. Usually, at the time of equipment initialization, as a part of self-check, the The first Editorial discusses the issue "Blood Banker's Ethical Dilemma: To Assure Quality or Contain Costs" and the second discusses the issue "Legal Issues in Transfusion Medicine."
Being aware that the prime readership comes from the member countries of the AATM, and three of these member countries belong to the WHO Eastern Mediterranean Region (EMR) -Afghanistan, Iran, and Pakistan, we feel the need to comment on both Editorials as they reflect a general state of development of the blood supply and clinical use that deserves a focused attention and sustained support.
All countries have agreed to try to achieve universal health coverage (UHC) by 2030, as part of the Sustainable Development Goals (SDG). [3] UHC provides access to quality essential health services; safe, effective, and affordable essential medicines and vaccines; and protection from financial risk. [4] Blood and blood products are essential medicines, [5] and universal and timely access to these products, and their appropriate use, are essential components of good health care provision. Governments are responsible for ensuring the ethical and equitable procurement, distribution, and use of these products through the establishment of a nationally coordinated and effectively regulated blood supply. [6] It is the governments' core duty to protect and promote public health, also protect the fundamental rights and freedoms of individuals, which may be endangered by unethical practices of procurement or distribution. [7] Indeed, the blood and its components are invaluable and shall be shared on a voluntary and nonremunerated basis. The recipient therefore shall not be charged for the "gift of life" but be asked to contribute in the costs of the service of availability, accessibility, efficacy, and safety of the products produced from the invaluable source material "human blood." Since Landsteiner, [8] attention has been given to the many facets of the transfusion medicine diamond. The key elements of the provision of a safe and efficacious transfusion practice have been formulated and spread out over the world by WHO since the first World Health Assembly resolution in 1975 [9] and subsequent development and implementation of the Quality Management education materials in the 1990s and beyond. [10] Both editorials do not mention these principles which include the legal principles of product liability and consumer rights protection. WHO EMR has developed a 10-year regional strategic framework for blood safety and availability [11] that will contribute toward achieving UHC and SDG on health. The strategic framework was endorsed by 22 countries in the region, [12] including Afghanistan, Iran, and Pakistan The framework guides and advises countries on availability and safety of blood transfusion vein-to-vein along 5 key issues which include strengthening leadership and governance, coordination and collaboration through development of a centralized information management system, strengthen provision of safe blood and blood products, promote their appropriate clinical use, and strengthen quality management system throughout the transfusion chain including hemovigilance.
The importance of the message is in a strong legislative and regulatory framework (governance commitment) and competent leadership to implement and follow national standards (quality and technical) and guidelines for creating and sustaining public and clinical awareness on
